Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 3/20 | 0.37 |
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5080069 | 0.89 | CDK1 (0.40) | RAB9AHTTCDK1TMIGD3ADORA2A | |
| SCHEMBL5086082 | 0.83 | NPC1 (0.36) | RAB9ASMN1; SMN2NPC1HPGDABL1 | |
| SCHEMBL5083000 | 0.82 | ADORA1 (0.41) | SMN1; SMN2ABL1RIN1ADORA2AADORA1 | |
| SCHEMBL5082973 | 0.81 | ADORA1 (0.46) | ABL1RIN1ADORA2AADORA1ADORA2B | |
| SCHEMBL5083021 | 0.81 | ADORA1 (0.47) | ADORA2AADORA1ADORA2B | |
| SCHEMBL5082276 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2TP53LMNAHTTALOX15 | |
| SCHEMBL5080087 | 0.73 | ABL1 (0.42) | RAB9ASMN1; SMN2NPC1HPGDABL1 | |
| SCHEMBL5083648 | 0.72 | DNPH1 (0.37) | CDK1TMIGD3ADORA2AADORA1ADORA2B | |
| SCHEMBL5086065 | 0.68 | ABL1 (0.38) | RAB9ASMN1; SMN2NPC1HPGDABL1 | |
| SCHEMBL7644240 | 0.67 | HTT (0.68) | RAB9ASMN1; SMN2NPC1HPGDABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | RAB9A 4162/4885SMN1; SMN2 655/4885NPC1 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.